Loading clinical trials...
Loading clinical trials...
A Multicenter, Single-blind, Within-subject, Placebo-controlled Proof of Concept Study to Assess the Effect of Single Oral Doses of BGG492 on the Photoparoxysmal EEG Response in Patients With Photosensitive Epilepsy
This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Novartis Investigator Site
Bielefeld, Germany
Novartis Investigator Site
Kehl-Kork, Germany
Novartis Investigator Site
Kiel, Germany
Novartis Investigator Site
Radeberg, Germany
Start Date
October 1, 2008
Primary Completion Date
September 1, 2010
Completion Date
September 1, 2010
Last Updated
September 23, 2016
13
ACTUAL participants
BGG492
DRUG
BGG492
DRUG
Placebo
DRUG
Lead Sponsor
Novartis Pharmaceuticals
NCT03790137
NCT03686033
NCT00609245
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions